Insights Into Hologic (HOLX) Q2: Wall Street Projections for Key Metrics

Core Insights - Hologic (HOLX) is expected to report quarterly earnings of $1.02 per share, reflecting a year-over-year decline of 1% and revenues of $1 billion, which is a 1.6% decrease compared to the previous year [1] - The consensus EPS estimate has been adjusted downward by 0.1% over the past 30 days, indicating a reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Estimates - Analysts project 'Revenues- Diagnostics- Cytology and Perinatal' at $119.94 million, a decrease of 0.5% year-over-year [5] - 'Revenues- Diagnostics- Molecular Diagnostics' is estimated to be $328.58 million, reflecting an increase of 1.8% from the prior year [5] - 'Revenues- Diagnostics- Blood Screening' is expected to reach $4.99 million, indicating a significant decline of 27.6% [6] - 'Revenues- Breast Health- Breast Imaging' is projected at $282.58 million, down 7.9% from the previous year [6] - 'Revenue- Skeletal Health' is estimated at $18.00 million, showing a decline of 33.6% [6] - Total Breast Health revenue is expected to be $369.50 million, a decrease of 3.9% year-over-year [7] - Total Diagnostics revenue is projected at $453.52 million, reflecting a slight increase of 0.8% [7] - 'Revenue- GYN Surgical' is estimated to reach $161.11 million, indicating a growth of 3.3% [7] - 'Revenues- Breast Health- Interventional Breast Solutions' is expected to be $86.91 million, showing an increase of 11.6% from the prior year [8] Stock Performance - Over the past month, Hologic shares have declined by 5.4%, compared to a 4.3% decline in the Zacks S&P 500 composite [8] - Hologic holds a Zacks Rank 3 (Hold), suggesting that its performance is likely to align with the overall market in the near term [8]